The oral selective oestrogen receptor degrader (SERD) AZD9496 is comparable to fulvestrant in antagonising ER and circumventing endocrine resistance

BACKGROUND: The oestrogen receptor (ER) is an important therapeutic target in ER-positive (ER+) breast cancer. The selective ER degrader (SERD), fulvestrant, is effective in patients with metastatic breast cancer, but its intramuscular route of administration and low bioavailability are major clinic...

Полное описание

Сохранить в:
Библиографические подробности
Опубликовано в: :Br J Cancer
Главные авторы: Nardone, Agostina, Weir, Hazel, Delpuech, Oona, Brown, Henry, De Angelis, Carmine, Cataldo, Maria Letizia, Fu, Xiaoyong, Shea, Martin J., Mitchell, Tamika, Veeraraghavan, Jamunarani, Nagi, Chandandeep, Pilling, Mark, Rimawi, Mothaffar F., Trivedi, Meghana, Hilsenbeck, Susan G., Chamness, Gary C., Jeselsohn, Rinath, Osborne, C. Kent, Schiff, Rachel
Формат: Artigo
Язык:Inglês
Опубликовано: Nature Publishing Group UK 2018
Предметы:
Article
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC6353941/
https://ncbi.nlm.nih.gov/pubmed/30555156
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41416-018-0354-9
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы